ADA and panuveitis: This corresponds with the algorithm of treatment of BD uveitis by Karadag et al. from 2020, that included IFX or IFN-alpha as first-line therapy for acute sight-threatening uveitis at presentation together with high-dose intravenous corticosteroids (CSs) [7]; however, they suggested only AZA and CsA as the first-line therapy for posterior uveitis or panuveitis together with oral CSs, whereas IFX, ADA or IFN-alpha were indicated in refractory and/or recurrent cases [7].